Tecnotree Reports Impressive Q1 2023 Results with Strong Growth and Increased Profitability
18.4.2023 12:04:00 EEST | Business Wire | Press release
Tecnotree, a global digital platform and services leader for 5G and cloud-native technology, announced its financial results for the first quarter of 2023, demonstrating impressive growth and success. The company has achieved a remarkable 17% growth in net sales, marking its strongest Q1 revenue performance in the past four years. This exceptional growth was primarily driven by the Americas Region, which contributed significantly to Tecnotree's revenue expansion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230418005718/en/
Tecnotree Reports Impressive Q1 2023 Results with Strong Growth and Increased Profitability (Graphic: Business Wire)
Key Q1 Highlights of the financial results:
• Net sales were EUR 15.5 million with a growth of 17.0% as compared to last year
• The operating result was EUR 3.6 million, an increase of 80.5%
• The net result was EUR 1.8 million, an increase of 79.2%
• Order book at the end of the period stood at EUR 67.8 million
• Earnings per share were EUR 0.01
Padma Ravichander, CEO of Tecnotree Corporation, said, “Tecnotree has achieved several significant milestones in the first quarter of 2023, demonstrating its unwavering commitment to innovation, excellence, and customer satisfaction. Our continued growth is fuelled by the increasing demand for our products and solutions, with strong ongoing deliveries of the Digital Stack across the Middle East, Africa, and Europe, and we anticipate receiving increasing orders from new and existing Tier 1 operators. This growth is a result of our continued investment in R&D, particularly in our Tecnotree Sensa AI/ML engineering platform and multi-cloud technologies, which has further cemented our position as a leader in the AI/ML space.”
She further commented, “We're committed to expanding our digital products and services to reach new frontiers in Telco, Healthcare, and Fintech industries in 2023 and beyond. Our Moments platform and Fintech offerings are poised to revolutionize the way digital service providers and ecosystem players collaborate to introduce innovative revenue models and empower digitally connected communities. We're excited to build new partnerships and leverage our expertise to make a significant impact in these new verticals."
Other significant milestones in the Quarter:
- Tecnotree has increased its research and development investments and launched Tecnotree Sensa AI/ML engineering platform, which has been integrated across its digital portfolio for Telecom, Fintech, and Social Commerce segments. The move has enabled the company to enhance its offerings and deliver more value to its customers.
- The company witnessed its highest Q1 growth in net sales and added two new Tier-1 logos from North America, Radian in the USA and Telus in Canada. Furthermore, an existing customer, Claro Peru, expanded its digital portfolio to include Sensa AI for customer 360 experience management. This expansion has helped Tecnotree to strengthen its customer base and position itself as a leader in the industry.
- Tecnotree's profitability has improved, despite increasing its investments in research and development. The company has implemented strong cost-saving measures in its human capital to achieve this, demonstrating its commitment to sustainable growth.
- Tecnotree has been recognized by Gartner’s Market Guide again in Q1 of 2023 for Customer Experience and Management for Telecom Operators and has been consistently recognized for the same since 2020. Additionally, Tecnotree has been recognized by Gartner’s Market Guide for Revenue Monetisation and Management for Telecom Operators consistently since 2020. The recognition reinforces Tecnotree's reputation as a reliable and innovative partner in the industry.
- Tecnotree continues to be among the leading vendors in TM Forum Open APIs certification standards, with 44 APIs certified by the industry standards body, highlighting the company’s commitment to interoperability and collaboration.
- Tecnotree Moments, the company's telecom monetisation platform, has been awarded the Best Telecom Monetisation Platform by the Government of Dubai at the ftNFT Awards. This recognition is a testament to Tecnotree's leadership in cutting-edge technologies and its ability to drive further innovation with humanized AI-enabled experiences.
About Tecnotree
Tecnotree is a 5G-ready digital Business Support System (BSS) player, with AI/ML capabilities and multi-cloud extensibility. Tecnotree is among the first companies in the world to be Platinum Certified by TM Forum Open API standards, and our agile and open-source Digital BSS Stack comprises the full range (order-to-cash) of business processes and subscription management for telecom and other digital services industries creating opportunities beyond connectivity. Tecnotree also provides Fintech and B2B2X multi-experience digital marketplace to its subscriber base through the Tecnotree Moments platform to empower digitally connected communities across gaming, health, education, OTT, and other vertical ecosystems. Tecnotree is listed on Helsinki Nasdaq (TEM1V).
For more information, please visit www.tecnotree.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230418005718/en/
Contact information
Padma Ravichander, Tecnotree CEO
Email: marketing@tecnotree.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom